Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 300 of 2051 entries
View as:

A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)

Phase: N/A Priority: Normal
NCT ID: NCT03692871 Org: User:
Start: 12/14/18 End: 03/26/21 Due: 03/26/22

Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00326183 Org: User:
Start: 03/26/07 End: 01/15/08 Due: 01/15/09

A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)

Phase: N/A Priority: Normal
NCT ID: NCT02531373 Org: User:
Start: 09/15/15 End: 04/14/17 Due: 04/14/18

Placebo Controlled Metformin and Sulfonylurea Combination Study in Patients With Type 2 Diabetes (0767-025)

Phase: N/A Priority: Normal
NCT ID: NCT00543751 Org: User:
Start: 01/31/03 End: 11/30/03 Due: 11/30/04

A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)

Phase: N/A Priority: Normal
NCT ID: NCT01605396 Org: User:
Start: 07/04/12 End: 03/15/18 Due: 03/15/19

Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)

Phase: N/A Priority: Normal
NCT ID: NCT00377065 Org: User:
Start: - End: - Due: -

Remicade Safety Line (Study P03236)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00748826 Org: User:
Start: 08/31/02 End: 12/31/10 Due: 12/31/11

SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)

Phase: N/A Priority: Normal
NCT ID: NCT03552549 Org: User:
Start: 08/05/98 End: 02/19/01 Due: 02/19/02

The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)

Phase: N/A Priority: Normal
NCT ID: NCT00392171 Org: User:
Start: 06/09/06 End: 09/15/09 Due: 09/15/10

The OBSTACLE Hypoglycemia Study (MK-0000-158)

Phase: N/A Priority: Normal
NCT ID: NCT00907881 Org: User:
Start: 08/31/09 End: 05/31/10 Due: 05/31/11

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

Phase: N/A Priority: Normal
NCT ID: NCT05952856 Org: User:
Start: 08/10/23 End: 08/15/25 Due: 08/15/26

MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)

Phase: N/A Priority: Normal
NCT ID: NCT00506077 Org: User:
Start: 12/31/07 End: 10/31/08 Due: 10/31/09

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

Phase: N/A Priority: Normal
NCT ID: NCT06780111 Org: User:
Start: 08/07/25 End: 02/21/31 Due: 02/21/32

A Study of Carbamazepine (CBZ) and MK-8527 in Healthy Adult Participants (MK-8527-012)

Phase: N/A Priority: Normal
NCT ID: NCT06893081 Org: User:
Start: 04/28/25 End: 07/11/25 Due: 07/11/26

A Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis

Phase: N/A Priority: Normal
NCT ID: NCT00407927 Org: User:
Start: 12/31/06 End: 03/31/07 Due: 03/31/08

Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise (0431-158)

Phase: N/A Priority: Normal
NCT ID: NCT00832390 Org: User:
Start: 02/14/07 End: 07/11/08 Due: 07/11/09

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)

Phase: N/A Priority: Normal
NCT ID: NCT00034944 Org: User:
Start: 01/24/02 End: 12/17/03 Due: 12/17/04

Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)

Phase: N/A Priority: Normal
NCT ID: NCT01440595 Org: User:
Start: 11/28/11 End: 05/01/12 Due: 05/01/13

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

Phase: N/A Priority: Normal
NCT ID: NCT04626518 Org: User:
Start: 12/17/20 End: 05/31/26 Due: 05/31/27

Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)

Phase: N/A Priority: Normal
NCT ID: NCT02099110 Org: User:
Start: 04/22/14 End: 05/26/16 Due: 05/26/17

Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00108017 Org: User:
Start: 04/30/05 End: 07/31/06 Due: 07/31/07

Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00694083 Org: User:
Start: 06/10/08 End: 09/06/09 Due: 09/06/10

MK0524A Bioequivalence Study (0524A-059)

Phase: N/A Priority: Normal
NCT ID: NCT00944645 Org: User:
Start: 10/31/06 End: 01/31/07 Due: 01/31/08

A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219)

Phase: N/A Priority: Normal
NCT ID: NCT01732458 Org: User:
Start: 02/12/13 End: 09/26/16 Due: 09/26/17

To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01284348 Org: User:
Start: 03/25/11 End: 09/21/12 Due: 09/21/13